Biomarkers in Uterine Leiomyoma

Overview

Journal Fertil Steril

Specialty Reproductive Medicine

Date 2012 Dec 4

PMID 23200685

Citations 13

Authors

Gary Levy

Micah J Hill

Torie C Plowden

William H Catherino

Alicia Y Armstrong

Affiliations

Soon will be listed here.

Abstract

Biomarkers are biologic compounds that are easily accessible and reflect normal physiology or pathology. They are useful in a variety of clinical situations that involve detection of subclinical disease, risk stratification, preoperative planning, and monitoring treatment. A useful intervention needs to exist for a biomarker to be an effective tool. Many compounds have been investigated as potential biomarkers for the diagnosis and surveillance of uterine leiomyomas. Most of these compounds demonstrate subtle differences among patients when leiomyomas are compared with controls. The compounds investigated lack the diagnostic accuracy necessary to add any benefit to the current available modalities used to diagnose and monitor uterine leiomyomas.

Citing Articles

The Impact of Adenomyosis on Pregnancy.

Tsikouras P, Kritsotaki N, Nikolettos K, Kotanidou S, Oikonomou E, Bothou A Biomedicines. 2024; 12(8).

PMID: 39200389 PMC: 11351718. DOI: 10.3390/biomedicines12081925.

The correlation between women's various gynaecological diseases to ovarian cancer in Sulaimaniyah City, Iraq.

Karim S, Fattah C J Int Med Res. 2023; 51(4):3000605231158949.

PMID: 37013263 PMC: 10074628. DOI: 10.1177/03000605231158949.

PLP1 may serve as a potential diagnostic biomarker of uterine fibroids.

Cai L, Liao Z, Li S, Wu R, Li J, Ren F Front Genet. 2022; 13:1045395.

PMID: 36386836 PMC: 9662689. DOI: 10.3389/fgene.2022.1045395.

Benign metastasising leiomyoma: a rare disease and a diagnostic challenge.

Li M, Lee A, Wong W, Tan K BMJ Case Rep. 2022; 15(7).

PMID: 35835485 PMC: 9289031. DOI: 10.1136/bcr-2021-248575.

Parasitic leiomyoma in the trocar site after laparoscopic myomectomy: A case report.

Roh C, Kwon H, Jung M World J Clin Cases. 2022; 10(9):2895-2900.

PMID: 35434089 PMC: 8968796. DOI: 10.12998/wjcc.v10.i9.2895.

References

Myers E, Barber M, Gustilo-Ashby T, Couchman G, Matchar D, McCrory D . Management of uterine leiomyomata: what do we really know?. Obstet Gynecol. 2002; 100(1):8-17. DOI: 10.1016/s0029-7844(02)02019-7. View

Blake R . Leiomyomata uteri: hormonal and molecular determinants of growth. J Natl Med Assoc. 2007; 99(10):1170-84. PMC: 2574407. View

Baban R . Serum protein and prolactin as diagnostic markers. Saudi Med J. 2009; 30(11):1411-5. View

Bast Jr R, Skates S, Lokshin A, Moore R . Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer. 2012; 22 Suppl 1:S5-8. PMC: 3389992. DOI: 10.1097/IGC.0b013e318251c97d. View

Alvarez C, Lodeiro M, Theodoropoulou M, Camina J, Casanueva F, Pazos Y . Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation. Endocr Relat Cancer. 2009; 16(2):599-611. DOI: 10.1677/ERC-08-0192. View

Anderson G, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe J . Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010; 102(1):26-38. PMC: 2802285. DOI: 10.1093/jnci/djp438. View

Rebmann V, Regel J, Stolke D, Grosse-Wilde H . Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2004; 13(5):371-7. DOI: 10.1016/s1044-579x(03)00028-2. View

Moore R, Miller M, Steinhoff M, Skates S, Lu K, Lambert-Messerlian G . Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012; 206(4):351.e1-8. PMC: 3985608. DOI: 10.1016/j.ajog.2011.12.029. View

Zhou Y, Wu B, Li H . [The value of serum CA125 assays in the diagnosis of uterine adenomyosis]. Zhonghua Fu Chan Ke Za Zhi. 1996; 31(10):590-3. View

10.

Agdi M, Tulandi T . Minimally invasive approach for myomectomy. Semin Reprod Med. 2010; 28(3):228-34. DOI: 10.1055/s-0030-1251479. View

11.

Christenson R, Duh S . Methodological and analytic considerations for blood biomarkers. Prog Cardiovasc Dis. 2012; 55(1):25-33. DOI: 10.1016/j.pcad.2012.05.001. View

12.

Lin C, Chen Y, Liu W, Chou H, Chang Y, Lin S . Proteomic identification of plasma biomarkers in uterine leiomyoma. Mol Biosyst. 2011; 8(4):1136-45. DOI: 10.1039/c2mb05453a. View

13.

Meier U, Gressner A . Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50(9):1511-25. DOI: 10.1373/clinchem.2004.032482. View

14.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762):656-60. DOI: 10.1038/45230. View

15.

Agrawal R, Prelevic G, Conway G, Payne N, Ginsburg J, Jacobs H . Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril. 2000; 73(1):56-60. DOI: 10.1016/s0015-0282(99)00476-8. View

16.

Wu T, Yen T, Lai C . Clinical presentation and diagnosis of uterine sarcoma, including imaging. Best Pract Res Clin Obstet Gynaecol. 2011; 25(6):681-9. DOI: 10.1016/j.bpobgyn.2011.07.002. View

17.

Bowden W, Skorupski J, Kovanci E, Rajkovic A . Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays. Mol Hum Reprod. 2009; 15(9):563-8. PMC: 2725754. DOI: 10.1093/molehr/gap050. View

18.

Stamatopoulos C, Mikos T, Grimbizis G, Dimitriadis A, Efstratiou I, Stamatopoulos P . Value of magnetic resonance imaging in diagnosis of adenomyosis and myomas of the uterus. J Minim Invasive Gynecol. 2012; 19(5):620-6. DOI: 10.1016/j.jmig.2012.06.003. View

19.

Kolankaya A, Arici A . Myomas and assisted reproductive technologies: when and how to act?. Obstet Gynecol Clin North Am. 2006; 33(1):145-52. DOI: 10.1016/j.ogc.2005.12.008. View

20.

Gnanapavan S, Kola B, Bustin S, Morris D, McGee P, Fairclough P . The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002; 87(6):2988. DOI: 10.1210/jcem.87.6.8739. View